A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age

CONCLUSIONS: Three different lots of PCV20 demonstrated robust and consistent immunogenicity. The safety and tolerability of PCV20 was acceptable and similar to that of PCV13. (Clinicaltrials.gov: NCT03828617).PMID:34315611 | DOI:10.1016/j.vaccine.2021.07.004

Source: Vaccine - July 28, 2021 Category: Allergy & Immunology Authors: Nicola P Klein Paula Peyrani Kari Yacisin Nicole Caldwell Xia Xu Ingrid L Scully Daniel A Scott Kathrin U Jansen William C Gruber Wendy Watson Source Type: research